Drugs Analysis: Synribo
|出版日期||內容資訊||英文 12 Pages
|藥物分析:Synribo (omacetaxine) Drugs Analysis: Synribo|
|出版日期: 2017年12月07日||內容資訊: 英文 12 Pages||
提供著本報告提供慢性骨髓性白血病 (CML) 治療藥的Synribo (omacetaxine) 的相關調查，SWOT分析，藥物簡介，及臨床實驗資料等。
Synribo (omacetaxine mepesuccinate; Teva/Hospira) is a subcutaneously formulated, semisynthetic form of homoharringtonine, a naturally occurring alkaloid. In vitro studies show that Synribo binds to the ribosomal A-site cleft, inhibiting synthesis of a number of key oncoproteins. These oncoproteins include mcl-1 (an apoptosis inhibitor), cyclin-D1 (a promoter of cell proliferation), and c-Myc (a cell differentiation inhibitor).
Synribo has suffered due to its late entrance into the chronic myeloid leukemia (CML) market and an unfavorable subcutaneous administration route compared to other marketed drugs. The drug has displayed activity against T315I mutation-positive disease, but Iclusig (ponatinib; Takeda/Incyte/Otsuka) displays similar activity and is available in an orally administered formulation. Therefore, Synribo will continue to see only minimal uptake in CML.